FDA Approves Medtronic’s Arctic Front For ‘First-Line’ Treatment For AFib
The new approval allows Medtronic to promote cryoablation as the first option for patients with recurrent symptomatic paroxysmal atrial fibrillation. Previously, it was only approved for patients who had already tried to manage their atrial fibrillation with drugs.
You may also be interested in...
Results from two industry-supported clinical trials published in the last week offer more support for treating atrial fibrillation with catheter ablation rather than medication alone.
The deal, potentially worth more than $85m, will allow Acutus to get more revenue from its core AcQMap electrophysiology mapping technology and invest in the development of its pulsed field ablation system.
June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.